Argitalpenak (195)

2023

  1. A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets

    Neurodegenerative Disease Management, Vol. 13, Núm. 1, pp. 15-21

  2. Assisted Reproductive Techniques in Multiple Sclerosis: Recommendations from an Expert Panel

    Neurology and Therapy, Vol. 12, Núm. 2, pp. 427-439

  3. Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis

    Digital Health, Vol. 9

  4. Diagnosis and treatment of progressive multiple sclerosis: A position paper

    European Journal of Neurology, Vol. 30, Núm. 1, pp. 9-21

  5. ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs

    Multiple Sclerosis Journal

  6. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

    Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 29, Núm. 7, pp. 875-883

  7. European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs

    European Journal of Neurology

  8. Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary

    Neurodegenerative Disease Management, Vol. 13, Núm. 1, pp. 5-13

  9. Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence

    Multiple Sclerosis and Related Disorders, Vol. 69

  10. Monitoring response to disease-modifying treatment in multiple sclerosis

    Neurology Perspectives, Vol. 3, Núm. 2

  11. Ravulizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder

    Annals of Neurology

  12. Relapsing-remitting and primary progressive multiple sclerosis treated with ocrelizumab: A comparative study

    Multiple Sclerosis and Related Disorders, Vol. 69

  13. Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies

    Neurology(R) neuroimmunology & neuroinflammation, Vol. 10, Núm. 1

  14. Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience

    Frontiers in Neurology, Vol. 14

  15. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (I)

    Revista de neurologia, Vol. 77, Núm. 1, pp. 19-30

  16. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (II)

    Revista de neurologia, Vol. 77, Núm. 2, pp. 47-60

2022

  1. Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in

    Frontiers in Immunology, Vol. 13

  2. Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

    Multiple Sclerosis Journal, Vol. 28, Núm. 5, pp. 842-846

  3. Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology

    Frontiers in immunology, Vol. 13, pp. 842354

  4. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom

    PharmacoEconomics, Vol. 40, Núm. 3, pp. 323-339